By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
BioMetas Group, a leading preclinical contract research organization (CRO), and Life Science Nation (LSN), a global leader in life science commercialization and capital formation, have joined forces to launch a strategic cross-border accelerator alliance. This partnership aims to reshape how early-stage therapeutic startups are sourced, developed, and scaled, combining scientific execution with commercialization readiness to build globally fundable companies.
The new alliance links BioMetas Innovator (Singapore) and LSN Labs (Boston) into a fully integrated platform. Together, they will select and support elite early-stage therapeutic assets from their shared networks in North America, APAC, and Europe.
At the heart of the partnership is a joint service-for-equity model designed to address one of the most persistent challenges in early-stage biotechs: the capital gap between scientific promise and commercial viability. By providing critical services in exchange for equity, both accelerators aim to empower promising startups that might otherwise stall due to limited funding.
“The early-stage ecosystem often fails not because of science, but because of timing, execution, and lack of access,” said Simon Hua, Founder of BioMetas. “By partnering with LSN, we combine rigorous preclinical testing with a global commercialization platform to help these companies reach key inflection points and engage the world.”
BioMetas will deliver milestone-based development and scientific validation through its CRO services. With a team of over 150 experienced scientists and deep experience across oncology, immunology, and other diseases, BioMetas provides a full suite of preclinical services, including in vivo / in vitro pharmacology, PK/PD modeling, biomarker discovery, protein science, and IND enabling package studies. These capabilities are offered under a service-for-equity structure, allowing startups to generate high-value, decision-driving data before raising their first institutional capital.
LSN will provide its entrepreneurial education curriculum, global partnering and roadshow training, access to its proprietary investor and licensing partner database, BD Assist meeting scheduling, and the tools needed to prepare and execute global roadshow campaigns. Companies will also gain exposure by participating in the RESI global partnering conferences that connect startups with capital investors and business development teams annually at five international events.
Launching with a 20-company pilot cohort, the alliance will apply a shared diligence framework to evaluate scientific potential and commercial readiness. Participating startups will gain access to targeted development services, curated partner matching, and cross-border exposure to capital and licensing partners.
Too often, scientific founders are left to navigate commercialization alone. The new program provides a structured bridge from discovery to global market engagement, giving founders the tools, systems, and support to thrive.
“This alliance creates a new engine for global therapeutic innovation,” said Dennis Ford, Founder of Life Science Nation. “It’s not just about helping scientists become entrepreneurs — it’s about giving them the infrastructure, the partners, and the roadmap to succeed on a global stage.”
This initiative marks the first step in building a scalable venture-building infrastructure for early-stage therapeutics. As the platform expands, startups will gain access not only to services and education, but to a growing ecosystem of capital partners and strategic collaborators committed to advancing breakthrough innovation.
Media Contact:
info@lifesciencenation.com
www.lifesciencenation.com | www.biometasgroup.com
Tags: business, entrepreneurship, news, startups, technology, venture capital
Nick Sireau became a new father in 2000. However, the usual joys of parenthood were quickly cut short when Nick discovered his son had black bone disease, also known as alkaptonuria, a debilitating condition for which there was no treatment. Two years later a second son came into Nick’s life, similarly afflicted. Nick, a solar power entrepreneur, embarked on the journey of a lifetime to find a cure. Raising money any way he knew how, from half marathons to grants from the European Commission, Nick funded and led the research needed to repurpose a drug and get it approved for alkaptonuria. Click here to watch the incredible story of courage, resilience, and a refusal to give up that produced a near-perfect treatment for an ultra-rare disease that diminishes the lives of over 20,000 patients worldwide. Repurposed drugs for ultra-rare diseases rarely see the light of day due to lack of commercial incentive. Heroes like Nick, and rare disease patients everywhere, need policy-based help to provide the incentives for investors and pharmas to move more promising assets forward. At Life Science Nation, we are dedicated to connecting innovators with the capital they need to help patients. Join Nick and other heroes at Life Science Nation’s RESI conferences and become part of the solution.
Next Phase Newsletter 